2,053 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Purchased by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 2nd quarter, HoldingsChannel reports. The fund bought 2,053 shares of the biopharmaceutical company’s stock, valued at approximately $76,000.

A number of other institutional investors also recently modified their holdings of CLDX. Arizona State Retirement System increased its stake in shares of Celldex Therapeutics by 2.0% in the second quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock valued at $601,000 after buying an additional 325 shares during the period. Los Angeles Capital Management LLC increased its position in Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 638 shares during the period. CANADA LIFE ASSURANCE Co raised its holdings in Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Celldex Therapeutics by 10.0% in the 1st quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock worth $552,000 after purchasing an additional 1,194 shares during the period. Finally, Fisher Asset Management LLC boosted its stake in shares of Celldex Therapeutics by 6.2% in the 4th quarter. Fisher Asset Management LLC now owns 21,812 shares of the biopharmaceutical company’s stock valued at $865,000 after purchasing an additional 1,274 shares during the last quarter.

Analyst Upgrades and Downgrades

CLDX has been the topic of several recent analyst reports. Stifel Nicolaus started coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday, September 26th. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Finally, The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a report on Monday, September 30th. They set a “neutral” rating and a $45.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $61.14.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $30.65 on Friday. The firm has a 50-day moving average of $37.45 and a 200-day moving average of $37.93. Celldex Therapeutics, Inc. has a one year low of $22.11 and a one year high of $53.18. The company has a market cap of $2.03 billion, a P/E ratio of -10.75 and a beta of 1.55.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The firm had revenue of $2.50 million during the quarter, compared to analyst estimates of $1.13 million. As a group, research analysts expect that Celldex Therapeutics, Inc. will post -2.5 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.